Pharmaceutical Executive July 2014

July 2014 | Volume 0, Issue 0
Column
Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.
FDA officials willing to relocate to far-flung global cities should be congratulated for their herculean efforts to protect American patients. But funding cuts hamper the Agency's international presence.
By Pharmaceutical Executive Editors
As companies divest non-core assets in the form of spinouts to unlock value, the role of a strong new parent brand has become increasingly important.
Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.
From the Editor
A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.
Special Sponsored Section
By Pharmaceutical Executive Editors
Poland's pharma industry, the largest in Central and Eastern Europe, confronts the fallout from the government's controversial 2012 Reimbursement Act.
Features
By Pharmaceutical Executive Editors
Its only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.
As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.
WebMD CEO David Schlanger tells PharmExec how connecting patients with physicians through a robust digital platform can deliver quality of care, cost savings, and better health outcomes.
native1_300x100
lorem ipsum